重症筋無力症治療の世界市場レポート 2025年

重症筋無力症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.0％で22億6,000万米ドルに成長します。予測期間の成長は、生物製剤とモノクローナル抗体、遺伝子医療と精密医療、新興免疫調整剤、神経保護戦略、バイオシミラー医薬品に起因します。予測期間中の主な動向としては、デジタル治療、共同研究イニシアティブ、患者中心のアプローチ、実臨床エビデンスの活用、長期安全性モニタリングなどが挙げられます。

重症筋無力症の罹患率の増加は、今後の重症筋無力症治療市場の成長を促進すると予測されます。重症筋無力症は、骨格筋の疲労や筋力低下を特徴とする自己免疫性の神経筋疾患です。重症筋無力症の治療には、患者が状態を管理できるようにヘルスケアサービスやケアを提供することが含まれます。その結果、重症筋無力症の有病率の増加が治療市場の売上を伸ばしています。例えば、全米希少疾患機構が2022年1月に発表したデータによると、重症筋無力症の自己免疫性有病率は米国で10万人当たり14～40人と推定されています。さらに、2024年4月にAmerican Journal of Managed Careが発表した報告では、年間平均1,800件の診断に基づき、10万人当たりの発症率は4.32件、10万人年当たりの発症率は2.46件と推定されています。このように、重症筋無力症の有病率の増加が重症筋無力症治療市場の拡大に拍車をかけています。

ヘルスケア支出の増加が重症筋無力症治療市場の成長に拍車をかけています。ヘルスケア支出は、特定の地域、国、組織内のヘルスケア部門に割り当てられた総財源を表します。このような支出は、自己免疫性神経筋疾患である重症筋無力症（MG）の治療に不可欠であり、患者の最適なケア、症状管理、生活の質の向上をサポートします。例えば、2024年7月、米国を拠点とする専門家団体であり、医師や医学生によるロビー活動団体である米国医師会は、2022年の米国の医療支出は4.1％増加し、4兆5,000億米ドル、国民一人当たり1万3,493米ドルに達すると報告しました。したがって、ヘルスケア支出の増加が重症筋無力症治療市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界重症筋無力症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の重症筋無力症治療市場：成長率分析
• 世界の重症筋無力症治療市場の実績：規模と成長, 2019-2024
• 世界の重症筋無力症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界重症筋無力症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の重症筋無力症治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 手術
• その他の治療法
• 世界の重症筋無力症治療市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コリンエステラーゼ阻害剤
• コルチコステロイド
• 免疫抑制剤
• その他の薬剤の種類
• 世界の重症筋無力症治療市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他の用途
• 世界の重症筋無力症治療市場、医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗コリンエステラーゼ剤
• 免疫抑制剤
• モノクローナル抗体
• コルチコステロイド
• 世界の重症筋無力症治療市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胸腺摘出術
• 世界の重症筋無力症治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿交換
• 静脈内免疫グロブリン（IVIg）
• 支持療法

第7章 地域別・国別分析

• 世界の重症筋無力症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の重症筋無力症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 重症筋無力症治療市場：競合情勢
• 重症筋無力症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• Biogen Idec
• Astellas Pharma Inc.
• CSL Limited
• Chugai Pharmaceutical Co. Ltd.
• Grifols S.A
• UCB Inc.
• Mitsubishi Tanabe Pharma Corp.
• Genentech Inc.
• Horizon Therapeutics plc
• Amneal Pharmaceuticals Inc.
• Kedrion SpA
• CuraVac Inc.
• AryoGen Pharmed

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 重症筋無力症治療市場2029：新たな機会を提供する国
• 重症筋無力症治療市場2029：新たな機会を提供するセグメント
• 重症筋無力症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myasthenia gravis treatment encompasses the provision of healthcare services by healthcare providers to address and manage myasthenia gravis, an autoimmune neuromuscular disease characterized by fatigue and weakness in the skeletal muscles.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring.

The rise in the incidence of myasthenia gravis is anticipated to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigue and weakness in the skeletal muscles. Treatment for myasthenia gravis involves delivering healthcare services and care to help patients manage the condition. Consequently, the increasing prevalence of myasthenia gravis is enhancing sales in the treatment market. For instance, data published by the National Organization for Rare Disorders in January 2022 indicated that autoimmune myasthenia gravis has an estimated prevalence of 14-40 per 100,000 individuals in the United States. Additionally, a report from the American Journal of Managed Care in April 2024, based on an average of 1,800 annual diagnoses, estimated an incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Thus, the growing prevalence of myasthenia gravis is fueling the expansion of the myasthenia gravis treatment market.

Rising healthcare spending is fueling growth in the myasthenia gravis treatment market. Healthcare spending represents the total financial resources allocated to the healthcare sector within a given region, country, or organization. Such spending is essential for treating myasthenia gravis (MG), an autoimmune neuromuscular disorder, as it supports optimal patient care, symptom management, and enhanced quality of life. For example, in July 2024, the American Medical Association, a U.S.-based professional association and lobbying group of physicians and medical students, reported that health spending in the United States rose by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per capita. Therefore, increased healthcare spending is propelling the growth of the myasthenia gravis treatment market.

Product innovations are becoming a significant trend in the myasthenia gravis treatment market. Key companies in this sector are concentrating on developing new solutions to maintain their competitive edge. For example, in October 2023, UCB Pharma, a pharmaceutical company based in Belgium, announced that the US Food and Drug Administration (FDA) approved Zilucoplan for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval adds a new treatment option for managing gMG, which is characterized by muscle weakness stemming from an autoimmune response. ZILBRYSQ stands out as a self-administered, once-daily subcutaneous complement C5 inhibitor, offering a convenient alternative to the traditional intravenous therapies that have long been the standard for treating gMG.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In November 2023, Selecta Biosciences, Inc., a biotechnology company based in the United States, announced its merger with Cartesian Therapeutics for an undisclosed amount. This merger enhances Selecta's dedication to RNA cell therapies for autoimmune diseases, particularly myasthenia gravis (MG). The partnership aims to leverage Cartesian's advanced RNA-engineering platform and pipeline, which includes the promising rCAR-T therapy Descartes-08, to accelerate development and provide effective treatment options. Cartesian Therapeutics is also a US-based biotechnology company focused on developing potential treatments for generalized myasthenia gravis.

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myasthenia Gravis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myasthenia gravis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myasthenia gravis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myasthenia gravis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Surgery; Other Treatments
• 2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types
• 3) By End-Use: Hospitals; Clinics; Other End-Uses
• Subsegments:
• 1) By Medication: Anticholinesterase Agents; Immunosuppressants; Monoclonal Antibodies; Corticosteroids
• 2) By Surgery: Thymectomy
• 3) By Other Treatments: Plasmapheresis; Intravenous Immunoglobulin (IVIg); Supportive Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myasthenia Gravis Treatment Market Characteristics

3. Myasthenia Gravis Treatment Market Trends And Strategies

4. Myasthenia Gravis Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Myasthenia Gravis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myasthenia Gravis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myasthenia Gravis Treatment Market Growth Rate Analysis
• 5.4. Global Myasthenia Gravis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myasthenia Gravis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myasthenia Gravis Treatment Total Addressable Market (TAM)

6. Myasthenia Gravis Treatment Market Segmentation

• 6.1. Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.2. Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• Other Medication Types
• 6.3. Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Uses
• 6.4. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticholinesterase Agents
• Immunosuppressants
• Monoclonal Antibodies
• Corticosteroids
• 6.5. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thymectomy
• 6.6. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasmapheresis
• Intravenous Immunoglobulin (IVIg)
• Supportive Therapies

7. Myasthenia Gravis Treatment Market Regional And Country Analysis

• 7.1. Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myasthenia Gravis Treatment Market

• 8.1. Asia-Pacific Myasthenia Gravis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myasthenia Gravis Treatment Market

• 9.1. China Myasthenia Gravis Treatment Market Overview
• 9.2. China Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myasthenia Gravis Treatment Market

• 10.1. India Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myasthenia Gravis Treatment Market

• 11.1. Japan Myasthenia Gravis Treatment Market Overview
• 11.2. Japan Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myasthenia Gravis Treatment Market

• 12.1. Australia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myasthenia Gravis Treatment Market

• 13.1. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myasthenia Gravis Treatment Market

• 14.1. South Korea Myasthenia Gravis Treatment Market Overview
• 14.2. South Korea Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myasthenia Gravis Treatment Market

• 15.1. Western Europe Myasthenia Gravis Treatment Market Overview
• 15.2. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myasthenia Gravis Treatment Market

• 16.1. UK Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myasthenia Gravis Treatment Market

• 17.1. Germany Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myasthenia Gravis Treatment Market

• 18.1. France Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myasthenia Gravis Treatment Market

• 19.1. Italy Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myasthenia Gravis Treatment Market

• 20.1. Spain Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myasthenia Gravis Treatment Market

• 21.1. Eastern Europe Myasthenia Gravis Treatment Market Overview
• 21.2. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myasthenia Gravis Treatment Market

• 22.1. Russia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myasthenia Gravis Treatment Market

• 23.1. North America Myasthenia Gravis Treatment Market Overview
• 23.2. North America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myasthenia Gravis Treatment Market

• 24.1. USA Myasthenia Gravis Treatment Market Overview
• 24.2. USA Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myasthenia Gravis Treatment Market

• 25.1. Canada Myasthenia Gravis Treatment Market Overview
• 25.2. Canada Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myasthenia Gravis Treatment Market

• 26.1. South America Myasthenia Gravis Treatment Market Overview
• 26.2. South America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myasthenia Gravis Treatment Market

• 27.1. Brazil Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myasthenia Gravis Treatment Market

• 28.1. Middle East Myasthenia Gravis Treatment Market Overview
• 28.2. Middle East Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myasthenia Gravis Treatment Market

• 29.1. Africa Myasthenia Gravis Treatment Market Overview
• 29.2. Africa Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myasthenia Gravis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Myasthenia Gravis Treatment Market Competitive Landscape
• 30.2. Myasthenia Gravis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Myasthenia Gravis Treatment Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Baxter International Inc.
• 31.3. Biogen Idec
• 31.4. Astellas Pharma Inc.
• 31.5. CSL Limited
• 31.6. Chugai Pharmaceutical Co. Ltd.
• 31.7. Grifols S.A
• 31.8. UCB Inc.
• 31.9. Mitsubishi Tanabe Pharma Corp.
• 31.10. Genentech Inc.
• 31.11. Horizon Therapeutics plc
• 31.12. Amneal Pharmaceuticals Inc.
• 31.13. Kedrion SpA
• 31.14. CuraVac Inc.
• 31.15. AryoGen Pharmed

32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market

34. Recent Developments In The Myasthenia Gravis Treatment Market

35. Myasthenia Gravis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Myasthenia Gravis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myasthenia Gravis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myasthenia Gravis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer